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BACKGROUND AND PURPOSE
Inhibitors of phosphodiesterase 5 (PDE5) affect signalling pathways by elevating cGMP, which is a second messenger involved
in processes of neuroplasticity. In the present study, the effects of the PDE5 inhibitor, sildenafil, on the pathological features of
Alzheimer’s disease and on memory-related behaviour were investigated.
EXPERIMENTAL APPROACH
Sildenafil was administered to the Tg2576 transgenic mouse model of Alzheimer’s disease and to age-matched negative
littermates (controls). Memory function was analysed using the Morris water maze test and fear conditioning tasks.
Biochemical analyses were performed in brain lysates from animals treated with saline or with sildenafil.
KEY RESULTS
Treatment of aged Tg2576 animals with sildenafil completely reversed their cognitive impairment. Such changes were
accompanied in the hippocampus by a reduction of tau hyperphosphorylation and a decrease in the activity of glycogen
synthase kinase 3b (GSK3b) and of cyclin-dependent kinase 5 (CDK5) (p25/p35 ratio). Moreover, sildenafil also increased
levels of brain-derived neurotrophic factor (BDNF) and the activity-regulated cytoskeletal-associated protein (Arc) in the
hippocampus without any detectable modification of brain amyloid burden.
CONCLUSIONS AND IMPLICATIONS
Sildenafil improved cognitive functions in Tg2576 mice and the effect was not related to changes in the amyloid burden.
These data further strengthen the potential of sildenafil as a therapeutic agent for Alzheimer’s disease.
Abbreviations
Ab, b-amyloid; Arc, activity-regulated cytoskeletal-associated protein; BDNF, brain-derived neurotrophic factor; CDK5,
cyclin-dependent kinase 5; CREB, cAMP response element binding; CS, conditioned stimulus; GSK3b, glycogen synthase
kinase 3b; IEG, immediate early gene; MWM, Morris water maze; US, unconditioned stimulus
Introduction
Phosphodiesterases (PDEs) are enzymes that hydrolyse the
cyclic nucleotides cAMP or cGMP, which act as second
messengers in intracellular signalling and in processes of
neuroplasticity, such as long-term potentiation (Frey et al.,
1993; Son et al., 1998). PDE inhibitors affect signalling path-
ways by elevating cAMP and/or cGMP levels, which may
ultimately lead to gene transcription through activation of
cAMP response element binding (CREB) (Impey et al., 1996; Lu
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et al., 1999). CREB-dependent gene expression has been
shown to underlie long-term memory formation in several
vertebrate and invertebrate species, probably through the
formation of new synaptic connections (Tully et al., 2003).
The pathological signs of Alzheimer’s disease include (i)
the presence of plaques (composed of deposits of amyloid
filaments) and neurofibrillary tangles (composed of deposits
of hyperphosphorylated tau) surrounded by altered neurite
processes and glia; (ii) the loss of synapses; and (iii) a degen-
eration of the neurons (Selkoe, 2002). One of the earliest
manifestations of Alzheimer’s disease is the inability of
affected individuals to form new memories. Memory impair-
ment appears to significantly predate the death of nerve cells,
implying that neuronal dysfunction is responsible for the
pathophysiology of early stage Alzheimer’s disease. Adminis-
tration of sildenafil, a selective PDE5 inhibitor, activates the
NO/cGMP pathway and significantly increases brain cGMP
levels (Hartell, 1996; Prickaerts et al., 2002a,b; Zhang et al.,
2002; Puerta et al., 2009). PDE5 inhibitors constitute an effec-
tive treatment for erectile dysfunction; however, the presence
of PDEs in various regions of the CNS (Loughney et al., 1998;
Reyes-Irisarri et al., 2005) and the fact that cGMP has been
recognized as a second messenger of key neural phenomena
such as synaptic plasticity (Haghikia et al., 2007; Paul et al.,
2008) substantiate the potential use of PDE inhibitors for
neurological disorders. Moreover, animal studies have shown
that sildenafil enhances memory in several models (Prickaerts
et al., 2002b; Rutten et al., 2005) and attenuates memory
impairment induced by NO synthase (NOS) inhibition
(Devan et al., 2006; 2007). Another study shows that sildena-
fil, dose-dependently, improves performance in the object
retrieval task in cynomolgus macaques (Rutten et al., 2008).
Cognitive dysfunction by blockade of muscarinic cholinergic
receptor (Devan et al., 2004), diabetes or electroconvul-
sive shock (Patil et al., 2006) is also reversed by sildenafil
treatment.
Glycogen synthase kinase 3b (GSK3b) and cyclin-
dependent kinase 5 (CDK5) are the most relevant kinases
involved in the pathogenic mechanisms of Alzheimer’s
disease through the phosphorylation at multiple sites of the
microtubule-binding protein, tau (Hanger et al., 1992; Man-
delkow et al., 1992; Ishiguro et al., 1993; Tomidokoro et al.,
2001; Elyaman et al., 2002; Liu et al., 2002; Otth et al., 2002;
Tsai et al., 2004). These kinases are associated with neuronal
death, the formation of paired helical filaments and neurite
retraction (Plattner et al., 2006; Twomey and Mccarthy, 2006;
Lopes et al., 2007). Therefore, inhibition of GSK3b and CDK5
activity has been proposed as a plausible therapeutic target for
the treatment of Alzheimer’s disease (Lau et al., 2002; Koh
et al., 2007). Puzzo et al. (2009) have recently demonstrated
that sildenafil produces an immediate and long-lasting
improvement of synaptic function, CREB phosphorylation
and memory in a mouse model of amyloid deposition. This
effect is also associated with a long-lasting reduction of
b-amyloid (Ab) levels. In the present study, we investigated
whether sildenafil could reverse the memory impairment in an
aged mouse model of Alzheimer’s disease with a pathology
showing both Ab deposits and hyperphosphorylated tau. Our
results demonstrated that sildenafil restored cognitive deficits
in this model of Alzheimer’s disease, without affecting the
Ab-burden.
Methods
Mouse model and treatment
All animal care and experimental procedures were in accor-
dance with European and Spanish regulations (86/609/CEE;
RD1201/2005) and were approved by the Ethical Committee
of the University of Navarra (no. 018/05). Behavioural studies
were carried out during light time (from 9 am to 2 pm). In this
study, Tg2576 Alzheimer’s disease transgenic mice, that
express the human 695-aa isoform of the amyloid precursor
protein (APP) containing the Swedish double mutation
(APPswe) [(APP695)Lys670→Asn, Met671→Leu] driven by a
hamster prion promoter, were used. The mice were on an
inbred C57BL/6/SJL genetic background. In the Tg2576 Alzhe-
imer’s disease mouse model, Ab peptide content in the brain
accumulates exponentially between 7 and 12 months of age
and mice show impaired memory in the water maze test at the
age of 12–15 months (Hsiao et al., 1996; Reed et al., 2010).
Based on effectiveness and toleration, the dose of sildena-
fil citrate (Viagra;Pfizer, New York, NY, USA) used in patients
with erectile dysfunction is 25–100 mg·day-1. The dosage of
sildenafil we used in the transgenic Alzheimer’s disease
mouse model is 15 mg·kg-1·day-1, which is equivalent to
85 mg·day-1 in humans, using the BSA-based dose calculation
(Reagan-Shaw et al., 2008).
First of all, the effect of sildenafil on the modulation of
memory-associated immediate early genes (IEGs), whose
expression may be altered in APP transgenic mice (Dickey
et al., 2004), was assessed. For this, 14- to 16-month-old
female Tg2576 mice were treated once daily with sildenafil
(15 mg·kg-1, i.p.) or saline for 5 days. The last injection was
given 30 min before being trained in a hippocampal-
dependent memory task and mice were killed 2 h after the
training session.
A second group of animals was used to test the long-term
effect of sildenafil in cognitive function. In this set of experi-
ments, 14- to 16-month-old female Tg2576 mice and age-
matched negative littermates (controls) were treated once
daily with sildenafil (15 mg·kg-1, i.p.) or saline for 5 weeks.
Morris water maze test
The Morris water maze (MWM) test was used to evaluate
spatial memory function in response to treatment with
sildenafil, as previously described (Hsiao et al., 1996; Rico-
baraza et al., 2009; Reed et al., 2010). After treatments, groups
of animals underwent spatial reference learning and memory
testing in the MWM. The water maze was a circular pool
(diameter 1.2 m) filled with water maintained at 20°C and
made opaque by the addition of non-toxic white paint. Mice
were trained for three consecutive days (8 trials per day)
swimming to a raised platform (visible-platform). No distal
visible cues were present during this phase. The same platform
location was used for all visible-platform sessions and was
changed for the hidden-platform training (submerged 1 cm
beneath the surface) conducted over 8 consecutive days (4
trials per day) with all visible distal cues present in this phase.
In both visible- and hidden-platform versions, mice were
placed pseudo-randomly in selected locations, facing towards
the wall of the pool to eliminate the potentially confounding
contribution of extramaze spatial cues. Each trial was termi-
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nated when the mouse reached the platform or after 60 s,
which ever came first. To test the retention, three probe trials
were performed at the beginning of 4th, 7th and the last day of
the test (day 9). In the probe trials the platform was removed
from the pool, and the percentage of time spent in the quad-
rant where the platform was previously set was recorded. All
trials were monitored by a camera above the centre of the pool
connected to a SMART-LD program (Panlab S.L., Barcelona,
Spain) for subsequent analysis of escape latencies, swimming
speed, path length and per cent time spent in each quadrant of
the pool during probe trials. All experimental procedures were
performed without knowledge of the treatments of the groups.
Fear conditioning test
After running the MWM, all the animals were trained in the
fear conditioning test. The conditioning procedure was carried
out in a StartFear system (Panlab S.L.) that allows recording
and analysis of the signal generated by the animal’s movement
through a high sensitivity Weight Transducer system. The
analogue signal is transmitted to the FREEZING and STARTLE
software modules through the load cell unit for recording
purposes and later analysis, in terms of activity/immobility.
The conditioning box is housed inside a soundproof chamber,
which minimized external stimulation during the condition-
ing and retention tests. The box was provided with a house
light that supplied dim illumination and with a floor grid
through which foot shocks could be administered.
On a training day, the mice were placed in the condition-
ing chamber for 2 min before the onset of a tone at 2800 Hz,
85 dB (conditioned stimulus, CS), which lasted for 30 s. The
last 2 s of the CS was paired with a 0.3 mA foot shock (uncon-
ditioned stimulus, US). After the shock and 10 s of resting the
same CS-US was delivered three consecutive times. Finally,
30 s after the last pair of CS-US, mice were returned to their
home cages. To test the effect of sildenafil in non-transgenic
mice, a lighter paradigm of training (1 CS-US pairing, Rico-
baraza et al., 2010) was used to avoid an overtraining that
may prevent the detection of a possible memory enhance-
ment. Twenty-four hours after the training, the mice were
placed again in the conditioning chamber; after 2 min of
exposure, the tone starts for a period of 2 min and freezing
time was assessed during the 4 min (no differences were
found in the freezing behaviour with or without the tone).
Freezing behaviour was defined as the lack of movement
except for breathing for at least 2 s, and was analysed to give
the percentage time freezing during exposure to the chamber.
The conditioning apparatus was controlled by the experi-
menter with specific software (Packwin, Panlab S.L.) running
on a PC computer.
Twenty-four hours after the fear conditioning test, the
animals were killed and the brains removed for biochemical
studies. One hemi brain was post-fixed in 4% paraformalde-
hyde, (PFA) followed by immersion in 2% PFA (24 h) and
cytoprotected in 30% sucrose solution in phosphate buffer
overnight at 4°C. Microtome sections (30mm thick) were cut
coronally, collected free floating and stored in 30% ethylene
glycol, 30% glycerol and 0.1 M phosphate buffer at -20°C
until processed. The cortex and hippocampus from the other
hemi brain were dissected, homogenized and processed as
described below for subsequent Western blot.
Determination of Ab levels
For analysis of total (soluble and insoluble) Ab42 burden, the
frontal cortex was homogenized in a buffer containing 5 M
guanidine HCl and 50 mM Tris-HCl, pH 8, protease inhibitors
(Complete Protease Inhibitor Cocktail, Roche, Barcelona,
Spain) and phosphatase inhibitors (0.1 mM Na3VO4, 1 mM
NaF). Ab42 levels detected with 3D6 antibody, specific for
amino acids 1–5 of Ab and shows no cross-reactivity to the
endogenous murine Ab protein at concentrations up to
1 ng·mL-1 (Johnson-Wood et al., 1997), were measured using
a sensitive sandwich ELISA kit from Biosource (Camarillo, CA,
USA) following the manufacturer’s instructions.
Immunohistochemistry
Floating tissue sections comprising hippocampal formation
were processed for 6E10 immunostaining following the pro-
tocol previously described by Ricobaraza et al. (2009). Briefly,
brain sections were incubated in blocking solution (PBS con-
taining 0.5% Triton X-100, 0.1% BSA and 2% normal goat
serum) for 2 h at room temperature. After washing, sections
were incubated in 70% formic acid for 7 min to expose the
epitope. Sections were incubated with the 6E10 antibody
(against amino acids 1–17 of Ab peptide, 1:200, Chemicon)
for 24 h at 4°C, washed with PBS and incubated with the
secondary antibody (Alexa Fluor 488 goat anti-mouse highly
cross-absorbed, Molecular Probes, Eugene, OR, USA, 1:400)
for 2 h at room temperature, protected from light. Fluores-
cence signals were detected with confocal microscope LSM
510 Meta (Carl Zeiss, Germany); objective Plan-neofluar 40¥/
1.3 oil DIC. Sections were evaluated in Z-series (0.4 mm steps)
using LSM 510 Meta software.
Production of protein extracts
Mice were killed by cervical dislocation and hippocampi
quickly dissected from the brains. Total tissue homogenates
were obtained by homogenizing the hippocampus in a cold
lysis buffer with protease inhibitors (0.2 M NaCl, 0.1 M
HEPES, 10% glycerol, 200 mM NaF, 2 mM Na4P2O7, 5 mM
EDTA, 1 mM EGTA, 2 mM DTT, 0.5 mM PMSF, 1 mM Na3VO4,
1 mM benzamidine, 10 mg·mL-1 leupeptin, 400 U·mL-1 apro-
tinin), centrifuged at 14 000¥ g 4°C for 20 min and the super-
natant was aliquoted and stored at -80°C. Total protein
concentrations were determined using the Bio-Rad Bradford
protein assay (Bio-Rad Laboratories).
For APP carboxy-terminal fragments determination, the
prefrontal cortex was homogenized in a buffer containing
SDS 2%, Tris-HCl (10 mM, pH 7.4), protease inhibitors (Com-
plete Protease Inhibitor Cocktail, Roche) and phosphatase
inhibitors (0.1 mM Na3VO4, 1 mM NaF). The homogenates
were sonicated for 2 min and centrifuged at 100 000¥ g for
1 h. Aliquots of the supernatant were frozen at -80°C and
protein concentration was determined by the Bradford
method using the Bio-Rad protein assay (Bio-Rad, Hercules,
CA, USA).
Immunoblotting
Protein samples were mixed with an equal volume of 2 ¥
Laemmli sample buffer, resolved onto SDS-polyacrylamide
gels and transferred to nitrocellulose membrane. The mem-
branes were blocked with 5% milk, 0.05% Tween-20 in PBS or
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TBS followed by overnight incubation with the following
primary antibodies: mouse monoclonal anti-p-tau AT8
(1:1000, Pierce Biotechnology, Inc. Rockford, USA), mouse
monoclonal anti-tau (1:5000, clone Tau46, Sigma-Aldrich, St.
Luis, MO, USA), rabbit polyclonal anti-pGSK3-Ser-9 (1:1000,
Cell Signalling Technology, Beverly, MA), rabbit polyclonal
anti-pAkt-Ser-473 (1:1000, Cell Signalling Technology), rabbit
monoclonal anti-Akt (1:1000, Cell Signalling Technology),
mouse polyclonal anti-pGSK3b-Tyr-216 (1:1000, BD Trans-
duction Laboratories, Lexington KT) rabbit polyclonal anti-
pCREB (1:500, Upstate-Millipore, Temecula, CA, USA), rabbit
polyclonal anti-CREB (1:1000, Cell Signalling Technology),
rabbit polyclonal anti-GSK3 (1:1000, Santa Cruz Biotechnol-
ogy, Santa Cruz, CA), rabbit polyclonal anti-c-fos (1:1000,
Santa Cruz Biotechnology), rabbit polyclonal anti-Arc
(1:1000, Santa Cruz Biotechnology), rabbit polyclonal anti-
brain-derived neurotrophic factor (BDNF) (1:1000, Osenses
Pty Ltd, Flagstaff Hill, SA, Australia) rabbit polyclonal anti-
p35/p25 (1:1000, Cell Signalling Technology), mouse mono-
clonal anti-actin (1:2000, Sigma-Aldrich, St. Louis, MO, USA)
and mouse monoclonal anti-tubulin (1:10000, Sigma-
Aldrich) in the corresponding buffer. Following two washes in
PBS/Tween-20 or TBS/Tween-20 and one PBS or TBS alone,
immunolabelled protein bands were detected by using HRP-
conjugated anti-rabbit or anti-mouse antibody (Santa Cruz;
dilution 1:5000) following an enhanced chemiluminescence
system (ECL, GE Healthcare Bioscience, Buckinghamshire,
UK), and autoradiographic exposure to Hyperfilm ECL (GE
Healthcare Bioscience). Quantity One software v.4.6.3 (Bio-
Rad) was used for quantification.
For Western blot analysis of APP-derived fragments, ali-
quots of the protein extracts were mixed with XT sample
buffer plus XT reducing agent or Tricine sample buffer (Bio-
Rad) and boiled for 5 min. Proteins were separated in a Cri-
terion precast Bis-Tris 4–12% gradient precast gel (Bio-Rad)
and transferred to nitrocellulose membranes. The membranes
were blocked with 5% milk, 0.05% Tween-20 in TBS followed
by overnight incubation with the following primary antibod-
ies: mouse monoclonal 6E10 (amino acids 1–17 of Ab peptide,
1:1000, Millipore, Billenica, MA), rabbit polyclonal anti-APP
C-terminal (amino acids 676–695) (1:2000, Sigma-Aldrich).
Data analysis and statistical procedures
The results were processed for statistical analysis using SPSS
package for Windows, version 15.0 (SPSS, Chicago, IL, USA).
Unless otherwise indicated, results are presented as mean 
SEM. In the MWM and fear conditioning test, escape laten-
cies during training were analysed using one-way ANOVA fol-
lowed by Scheffe’s post hoc test. In the MWM, Friedman’s test
was performed to determine the intra-group comparisons
over trials. Biochemical data were analysed using Kruskal–
Wallis test followed by Mann–Whitney post hoc test. Student’s
t-test was used in case two groups were compared.
Results
Sildenafil facilitated the induction of
memory-associated genes in Tg2576 mice
The activation of several immediate early genes (IEGs) is
crucial for long-term memory formation and amyloid depo-
sition in mice leads to impaired induction of the IEGs
expressed by exposure to a novel environment (Dickey et al.,
2004). To know whether sildenafil affected the induction of
IEGs, 14- to 16-month-old female Tg2576 mice were treated
with sildenafil (15 mg·kg-1, i.p.) or saline once a day for 5
days. Animals were given fear conditioning training 30 min
after the last injection and they were killed 2 h later
(Figure 1A). Gene expression in the hippocampus of trans-
genic mice that received saline or sildenafil were investigated
and compared with a group of aged- and strain-matched
non-transgenic mice that underwent the same procedure.
The genes for the synaptic activity-dependent proteins,
Arc and c-fos, are induced specifically in neurons engaged in
memory-encoding processes (Guzowski et al., 1999). Tg2576
mice had a marked reduction in c-fos expression (58  4%
reduction; P < 0.05), which was partially reversed by sildenafil
treatment (Figure 1B). Moreover, a significant increase (more
than twofold) in Arc expression was observed in the
sildenafil-treated group compared with Tg2576 saline-treated
mice; the level of Arc was similar in wild-type and saline-
treated Tg2576 mice (Figure 1C). An important mediator of
transcriptional changes associated to memory is the tran-
scription factor CREB protein (Dash et al., 1990). In the
Tg2576 group receiving sildenafil there was a significant
increase in the expression of hippocampal pCREB compared
with that of the transgenic group receiving saline (Figure 1D).
Collectively these data indicated that, in the hippocampus of
transgenic mice, the induction of IEGs, related to plasticity
and memory consolidation, was facilitated by sildenafil.
Sildenafil restored cognitive function in
Tg2576 mice
Cognitive impairment in Tg2576 animals starts at the age of
12 months in the MWM, the memory retention measured in
the probe trials being more affected (Hsiao et al., 1996; Wes-
terman et al., 2002; Reed et al., 2010). Studies were performed
comparing heterozygous transgenic Tg2576 females with age-
and strain-matched transgenic negative littermates (controls)
that were treated once daily with sildenafil (15 mg·kg-1, i.p.)
or saline for 5 weeks. No significant differences were found
among the groups during the training phase of the test
(visible-platform, Figure 2B), but there were significant differ-
ences in the spatial learning during the hidden-platform
between groups [F(2, 238) = 25.35; P < 0.001] (Figure 2C). Tg2576
mice treated with saline were impaired in their performance
in this test (days 2–8) compared with age-matched non-
transgenic mice (sildenafil- and saline-treated groups) or
Tg2576 mice treated with sildenafil.
Intra-group comparisons were analysed by the latencies in
the hidden-platform training over trials using the Friedman’s
repeated measure non-parametric test. The mean latencies
(time spent) to reach the platform decreased over the training
sessions for the non-transgenic mice treated with saline (c2r
= 30.50, P < 0.001), sildenafil (c2r = 28.00, P < 0.001) and for
the transgenic sildenafil-treated group (c2r = 26.40, P < 0.001,
Friedman’s test). On the contrary, the latencies exhibited by
the saline-treated transgenic group did not significantly
decrease over trials (c2r = 6.15, P > 0.05). The results indicate
that non-transgenic and sildenafil-treated animals tended to
learn correctly the platform location, whereas saline-treated
transgenic animals did not. Specifically, intra-group compari-
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sons of escape latencies showed a significant effect of the
training for the non-transgenic and the transgenic sildenafil-
treated groups. In contrast, transgenic saline-treated mice did
not show any significant reduction in their escape latencies
from days 2 to 8, compared with the first training day, reflect-
ing their inability to learn the platform location.
As a putative measurement of memory retention mice
swam in the pool with the platform removed. On day 4, no
significant differences were found among the groups. [F(2, 30) =
2.06, P = 0.10]. One-way ANOVA showed significant differences
between groups on days 7 and 9 [F(2, 30) = 8.96, P < 0.01 for day
7; and F(2, 30) = 5.94 P < 0.01, for day 9]. On days 7 and 9 the
proportion of time spent in the target quadrant was signifi-
cantly lower for transgenic mice treated with saline, com-
pared with the non-transgenic mice or the transgenic mice
that received sildenafil treatment. Transgenic sildenafil-
treated animals spent a proportion of time in the target
quadrant that did not differ from that of the age-matched
non-transgenic group (Figure 2D). The swim speed did not
differ significantly between groups and the distance data
exhibited the same pattern as the escape latency data (not
shown). These results indicate that sildenafil administered for
5 weeks restores the cognitive function of Tg2576 mice in the
MWM test. Sildenafil did not enhance memory in non-
transgenic mice in the MWM.
Mice were next given the fear conditioning test (contex-
tual learning), another hippocampus-dependent learning
task, where Tg2576 mice are impaired. As shown in Figure 2E,
Tg2576 mice that received the PDE5 inhibitor showed a freez-
ing response similar to that of the age-matched non-
transgenic mice and much more than saline-treated Tg2576
animals. These data confirm that sildenafil given chronically
ameliorated the memory deficits of this Alzheimer’s disease
mouse model.
The group of age-matched non-transgenic mice treated
for 5 weeks with sildenafil or saline were subjected to the
milder single CS-US pairing protocol, which allows detection
of subtler learning deficits. Freezing responses were signifi-
cantly enhanced by sildenafil (P < 0.05, Student’s t-test;
Figure 2F). These results show in non-transgenic animals that
sildenafil was able to improve cognition in an associative
learning paradigm.
Sildenafil effect did not correlate with a
decrease in Ab burden but with a decrease
in tau pathology
The effect of sildenafil on the Ab pathology in Tg2576 mice
was explored. The levels of Ab42 were determined in the
cerebral cortex by sandwich ELISA. As shown in Figure 3A, no
differences were observed in Ab42 levels in Tg2576 mice
Figure 1
The induction of memory-related genes in the hippocampus of aged Tg2576 mice is facilitated with sildenafil treatment. (A) Scheme showing
times of injection, training and death. Administration of sildenafil induces c-fos (B), Arc (C) and pCREB (D) following fear conditioning training.
Representative Western blot bands from hippocampal tissues of non-transgenic mice (Non-Tg), transgenic mice treated with saline (Tg2576
saline) or with sildenafil (Tg2576 sildenafil) are shown. The histograms represent the quantification of the immunoreactive bands in the Western
blot. Data are expressed as mean percentage (SEM) of the Non-Tg results (100%). n = 5–6 in each group. *P < 0.05, significantly different from
Tg2576 saline mice (Kruskal–Wallis followed by Mann–Whitney post hoc test).
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treated with saline compared with sildenafil-treated mice (no
Ab was detected in non-transgenic littermates, data not
shown). In support of this finding, no marked differences
between saline and sildenafil were observed when brain sec-
tions (including hippocampus and frontal cortex) from trans-
genic mice were labelled with the 6E10 antibody to detect Ab
load (Figure 3C). The levels of the C-terminal fragments (C83
and C99) of the APP, were analysed using Tris/tricine PAGE
16.5% gels for a better resolution. No differences in intensity
of any of the fragments were found between the two groups
of transgenic mice, suggesting that sildenafil does not affect
APP processing (Figure 3B).
The levels of phosphorylated tau were analysed in the
mice hippocampus using a phospho-specific antibody, AT8,
which recognizes aberrantly phosphorylated epitopes on
Ser202/Thr205. As shown in Figure 4A, phosphorylated tau
levels normalized to total tau (detected by the T46 antibody)
were significantly increased (twofold) in the hippocampus of
16-month-old Tg2576 mice receiving saline compared with
non-transgenic mice. Interestingly, transgenic mice treated
Figure 2
Chronic treatment with sildenafil reverses the learning deficit in aged Tg2576 mice. (A) Scheme showing times of injection, training and death.
Escape latency of the visible- (B) and hidden-platform (C) in the MWM test for the non-transgenic mice and transgenic mice treated with saline
(Non-Tg saline; Tg2576 saline) or sildenafil (Non-Tg sildenafil; Tg2576 sildenafil). Results are expressed as mean SEM (n = 10–12 in each group).
Tg2576 saline mice showed significantly longer escape latencies in the hidden-platform training thatn the Non-Tg saline group (**P < 0.01,
***P < 0.001, ANOVA with Scheffe’s post hoc test), Non-Tg sildenafil ($P < 0.01, $$$P < 0.001, ANOVA with Scheffe’s post hoc test) and to Tg2576
sildenafil-treated group (††P < 0.01, †††P < 0.001, ANOVA with Scheffe’s post hoc test). (D) Percentage of time spent searching for the target
quadrant of the probe test. Results are expressed as mean SEM n = 10–12 in each group. Tg2576 saline mice performed significantly worse than
Non-Tg saline (*P < 0.05, **P < 0.01, ANOVA with Scheffe’s post hoc test), Non-Tg sildenafil ($P < 0.05, $$P < 0.01, ANOVA with Scheffe’s post hoc
test) and Tg2576 sildenafil (†P < 0.05, ANOVA with Scheffe’s post hoc test) in the probe trial. (E) Tg2576 saline mice exhibited significantly less
freezing than the Non-Tg control mice (*P < 0.05, ANOVA with Scheffe’s post hoc tests) and Tg2576 sildenafil mice (†P < 0.05, ANOVA with Scheffe’s
post hoc tests) in the fear conditioning task. Results are expressed as mean  SEM n = 10–12 in each group. (F) Aged wild-type (Non-Tg) mice
receiving sildenafil for 5 weeks showed a significant enhancement of memory compared with Non-Tg saline-treated mice ($P < 0.05, Student’s
t-test). Results are expressed as mean  SEM n = 10–12 in each group.
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with sildenafil showed levels of tau phosphorylated at the
AT8 site similar to those in non-transgenic mice (Figure 4A).
As GSK3b, among other kinases, phosphorylates tau at Ser202
(AT8 immunoreactivity) (Hanger et al., 1992; Mandelkow
et al., 1992) the levels of the inactive GSK3b form, phospho-
rylated at Ser9 (pGSK3b-Ser9), and the active GSK3b form,
phosphorylated at Tyr216 (pGSK3b-Tyr216), normalized to total
GSK3b were measured. The reduced level of pGSK3b-Ser9 in
saline-treated transgenic animals was fully reversed by
sildenafil treatment (P < 0.05, Figure 4B). In contrast,
pGSK3b-Tyr-216 levels were increased in Tg2576 saline mice
and were normalized and became more similar to those
found in non-transgenic animals after the treatment with
sildenafil (Figure 4C). No changes were found in total GSK3b
normalized to actin (data not shown). The expression of
phosphorylated Akt in transgenic mice that received sildena-
fil was significantly different from that of the saline-treated
Tg2576 mice, which showed a significant reduction in pAkt
levels (normalized to total Akt) compared with non-
transgenic mice (P < 0.05; Figure 4D).
The kinase CDK5 is another kinase involved in tau phos-
phorylation in Alzheimer’s disease and contributes to phos-
phorylation of tau on Ser-202, Thr-205, Ser-235 and Ser-404
(Alvarez et al., 2001; Otth et al., 2002). Several authors have
shown that cleavage of p35 to p25 activates CDK5 and it is also
known that the proteolytic product p25 concentrates in
patients with Alzheimer’s disease (Patrick et al., 1999; Ahlija-
nian et al., 2000). In this context, the levels of CDK5 activator,
p25, referred to those of p35 were analysed, showing a signifi-
cant decrease (P < 0.01) in p25/p35 expression in the protein
extracts derived from Tg2576 mice receiving sildenafil com-
pared with transgenic saline-treated mice (Figure 4E). These
data suggest that Akt/GSK3 and/or p25/CDK5 pathways con-
tribute to the modulation by sildenafil of tau phosphorylation
in Tg2576 mice. Western blot analysis using protein extracts
obtained from non-transgenic mice that received sildenafil
Figure 3
No change is detected in the amyloid levels after chronic treatment with sildenafil in aged Tg2576 mice. (A) Levels of Ab42 in the transgenic mice
by ELISA. Results are expressed as mean  SEM n = 6–8 in each group. (B) Effects of chronic administration of sildenafil on full-length APP, and on
APP C-terminal fragments, C99 and C83, in aged transgenic mice. The histogram shows the quantification of the immunochemically reactive
bands in the Western blot of APP, C99 and C83 (representative bands are shown). Results are expressed as mean  SEM n = 5–6 in each group.
(C) Extracellular deposits stained with 6E10 antiserum were detected in both, saline- and sildenafil-treated Tg2576 mice. Amyloid deposits were
absent in age-matched (Non-Tg) control mice. Representative hippocampal sections of Non-Tg, saline- (Tg2576 saline) and sildenafil- (Tg2576
sildenafil) treated Tg2576 mice are shown. Scale bar = 100 mm.
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treatment did not reflect significant differences in the regula-
tion of the Akt/GSK3 and p25/CDK5 pathways compared with
the non-transgenic saline group (Figure 4).
Sildenafil effect correlated with increases in
BDNF and Arc expression
It has been suggested that the cGMP/PKG pathway also con-
tributes to the phosphorylation of CREB and can be respon-
sible for late phases of the memory consolidation processes.
Prickaerts et al. (2002b) suggested that the cGMP/PKG/CREB
pathway induces synthesis of proteins essential for memory
consolidation.
As inhibition of PDE5 causes an increase in cGMP levels,
to test if the cGMP/PKG/CREB pathway is involved in the
effects of sildenafil on memory, the expression of hippocam-
pal pCREB, that of its downstream target molecule, BDNF and
that of Arc were assessed in protein hippocampal extracts.
pCREB was not significantly induced in Tg2576 sildenafil-
treated mice (Figure 5A). In contrast, the low BDNF (mature,
13.5 KDa band) expression level found in the Tg2576 saline-
treated animals compared with non-transgenic group was
partially (and significantly, P < 0.05) restored after sildenafil
treatment (Figure 5B). Interestingly, in the group of non-
transgenic mice receiving sildenafil, the levels of hippocam-
pal mature BDNF were significantly increased compared with
those found in the group of non-transgenic saline-treated
mice (P < 0.001, Figure 5B). The level of Arc protein was
significantly increased (P < 0.05) in the Tg2576 sildenafil-
treated group compared with the transgenic group receiving
saline (Figure 5C). Treated animals displayed a marked
expression of this protein, which was higher (1.8-fold) than
in non-transgenic animals.
Compared with the saline-treated group, no significant
differences in pCREB (Figure 5A) and Arc (Figure 5C) expres-
Figure 4
Sildenafil regulates tau phosphorylation through GSK3b and CDK5 in Tg2576 transgenic mice. Chronic treatment with sildenafil modulates
phosphorylated tau (p-tau; A), pGSK3b-Ser9 (B), pGSK3b-Tyr216 (C), pAkt (D) and p25/35 (E) expression levels in aged transgenic Tg2576 mice
hippocampus but not in the non-transgenic (Non-Tg) group. Representative Western blot bands from hippocampal tissues of Non-Tg mice
receiving saline (Non-Tg saline) or sildenafil (Non-Tg sildenafil) and transgenic mice receiving saline (Tg2576 saline) or sildenafil (Tg2576
sildenafil) are shown. The histograms represent the quantification of the immunochemically reactive bands in the Western blot. Data are expressed
as mean percentage (SEM) of the results from the Non-Tg mice receiving saline (Non-Tg saline, 100%). n = 5–6 in each group. *P < 0.05;
**P < 0.01, significantly different from Tg2576 saline mice (Kruskal–Wallis followed by Mann–Whitney post hoc test).
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sion levels were detected in non-transgenic mice treated with
sildenafil. These data suggest that the regulation in the
expression of BDNF and Arc in the hippocampus of trans-
genic animals may be one of the molecular and cellular
mechanisms underlying the enhancement of cognition by
sildenafil.
Discussion and conclusions
The main finding in this study is the reversal of memory
deficits in the Tg2576 mouse model of AD using sildenafil, an
effect that appeared to be unrelated to a reduction in Ab
burden but related to the modulation of the pAkt/GSK3b/p-
tau and p25/CDK5 pathways (Figure 6).
Amyloid accumulation suppresses induction of genes
critical for memory consolidation in APP transgenic mice
(Dickey et al., 2004). The lack of induction of IEGs has the
predicted outcome of preventing memory consolidation (Jos-
selyn et al., 2001; Han et al., 2007). Training in sildenafil-
treated animals (exposure to a fear conditioning training 2 h
prior to being killed) enhanced the expression of the
memory-related genes, c-fos, Arc and pCREB (Figure 1) in the
hippocampus of transgenic mice. The increase in Arc and
pCREB expression following training is critically involved in
the early neural events responsible for the acquisition and for
the late phase of memory consolidation (Bernabeu et al.,
1997; Guzowski, 2002). Our results suggest that sildenafil
may enhance memory by extending the learning-induced Arc
and pCREB interval. Although other authors have described
that Ab induces a dysregulation in Arc (Dickey et al., 2003;
2004) and affects pCREB activation (Vitolo et al., 2002; Puzzo
et al., 2009), we did not find any significant difference
between transgenic mice and non-transgenic mice, in the
expression/activation of these genes after training. In con-
trast, c-fos induced by training was impaired in transgenic
mice and partially restored by sildenafil. A reduction in c-fos
expression in parallel with defective memory retention in the
Figure 5
Regulation of gene expression with sildenafil in mouse hippocampus. Western blot analysis of pCREB (A), mature BDNF (B) and Arc (C) in the
hippocampus of aged non-transgenic (Non-Tg) and transgenic (Tg2576) mice treated with saline or sildenafil. Representative Western blot bands
from hippocampal tissues of non-transgenic mice (Non-Tg), and transgenic mice (Tg2576) receiving saline (Non-Tg saline; Tg2576 saline) or
sildenafil (Non-Tg sildenafil; Tg2576 sildenafil) are shown. The histograms represent the quantification of the immunoreactive bands in the
Western blot. Data are expressed as mean percentage (SEM) of the results from versus Non-Tg mice receiving saline (Non-Tg saline, 100%).
n = 5–6 in each group. *P < 0.05, significantly different from Tg2576 sildenafil mice; ###P < 0.001, significantly different from Non-Tg saline mice
(Kruskal–Wallis followed by Mann–Whitney post hoc test).
Figure 6
Diagram of signalling pathways indicating the possible mechanism
by which sildenafil reverses the memory deficits in aged transgenic
Tg2576 mice. Sildenafil increases cGMP formation by inhibiting
PDE5, which can activate the pCREB pathway and its downstream
gene target BDNF, which consequently mediates Arc induction. The
activation of the pAkt pathway by sildenafil, and the inactivation of
p25/CDK5 could have contributed to the overall effects in the
memory reinstatement by decreasing phosphorylated tau in the
Tg2576 mice hippocampus.
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passive avoidance test was also detected in the brain of the
transgenic mouse line Tg-APP (Sw, V717F)/B6 at 13–15
months (Lee et al., 2004). Stanciu et al. (2001) have suggested
that c-fos production in the hippocampus accompanies the
memory consolidation of context-dependent fear condition-
ing. Altogether, the effect of sildenafil in the induction of
c-fos, Arc and pCREB may contribute to synaptic events nec-
essary for formation of new memories and may underlie the
ability to learn, as observed in sildenafil-treated transgenic
animals (Figure 2B).
The results of the 5 week treatment showed that sildenafil
restored cognitive impairment in aged Tg2576 mice in the
MWM and in the fear conditioning tasks. A similar effect was
previously described in APP/PS1 mice treated with sildenafil.
Interestingly, in non-transgenic mice, a sildenafil-triggered
enhancement in contextual memory was observed in the fear
conditioning test. It is noteworthy that whereas the sildenafil
effect on cognitive performance correlated with a decrease of
Ab levels in the cortex of APP/PS1 mice (Puzzo et al., 2009)
(plaques were not studied) this was not the case in aged
Tg2576 mice. These differences are likely due to the different
animal model used, and the timing of sildenafil treatment. In
fact, even though the APP/PS1 mice have an accelerated rate
of amyloid deposition, Puzzo et al. (2009) treated them before
the onset of Ab accumulation (Dineley et al., 2002), whereas
in the present study Tg2576 mice were treated long after the
onset of amyloid deposition. Nevertheless, further studies are
needed to determine whether sildenafil affects soluble Ab
oligomers and/or intraneuronal Ab. Our results point to a lack
of correlation between Ab deposits and memory function,
and importantly, prove that sildenafil reinstates cognitive
function in animals that display a high amyloid plaque
burden that resists sildenafil treatment. Other studies have
also failed in finding a correlation between a decrease in
deposited forms of Ab (such as plaques) and memory
improvement in Alzheimer’s disease models (Dodart et al.,
2002; Gong et al., 2004; Malm et al., 2007; Ricobaraza et al.,
2009). Moreover, amyloid plaques in humans do not neces-
sarily correlate with major cognitive deficits (Price and
Morris, 1999). This lack of correlation is indirectly supported
by reports of negligible therapeutic benefit in Alzheimer’s
disease patients of Ab42-lowering agents such as tarenflurbil
(Green et al., 2009).
Other pathological features of Alzheimer’s disease that
correlate robustly with cognitive decline are the paired helical
filaments and neurofibrillary tangles of hyperphosphorylated
tau aggregates (Giannakopoulos et al., 2003; Thind and
Sabbagh, 2007). Although the Tg2576 mice is a model of
Alzheimer’s disease amyloidosis, the presence of hyperphos-
phorylated tau epitopes (Ser199, Thr231/Ser235, Ser396 and Ser413)
has been consistently reported (Tomidokoro et al., 2001; Otth
et al., 2002; Sasaki et al., 2002 and shown here in Figure 4). Ab
amyloidosis activates the tau kinase pathway involving
GSK3b (via its phosphorylation at Tyr216) and CDK5 (through
calpain proteolysis of p35 to p25) and, subsequently, tau is
phosphorylated at sites (Tomidokoro et al., 2001; Otth et al.,
2002) that promote its accumulation and deposition.
The functional consequences of targeting the pAkt/GSK3b
pathway are of special relevance to attempt the restoration of
cognitive deficits associated with Alzheimer’s disease pathol-
ogy (Huang and Klein, 2006; Avila and Hernandez, 2007).
The increase induced by sildenafil in hippocampal pAkt and
pGSK3b-Ser9 levels, together with a parallel decrease in the
active pGSK3b-Tyr216 form, may be instrumental in the
decrease in tau phosphorylation observed in sildenafil-
treated transgenic mice. On the other hand, CDK5 phospho-
rylates tau at Ser199 and Ser202 (Tsai et al., 2004) and its activity
is deregulated when p35 is proteolytically cleaved by the
protease calpain to generate p25 activator (Lee et al., 2000;
Plattner et al., 2006). We found that p25/p35 ratio was
increased in Tg2576 mice and was reduced by sildenafil treat-
ment. This effect may contribute to the reduction in tau
phosphorylation and could be mediated by a reduction in
calpain activity, since PDE5 inhibitors reduce calpain activa-
tion (Puerta et al., 2010). Therefore, the decrease in the kinase
activity of GSK3b and CDK5 due to sildenafil may lead to a
decrease in tau phosphorylation (Ser202) in the hippocampus
of treated mice, possibly contributing to the reinstatement
of cognitive function (Hanger et al., 2009). Interestingly,
sildenafil seems to restore the pAkt/GSK3b or CDK5 pathways
when they are hyperactivated but not under normal condi-
tions. In fact, these pathways were not affected by sildenafil
when non-transgenic mice were analysed.
To stabilize changes in synaptic strength, neurons activate
a program of gene expression that results in alterations of
their molecular composition and structure. Of particular
interest is the examination of signalling pathways shown to
be important for the establishment of long-lasting synaptic
plasticity, such as the CREB signalling pathway and that of its
downstream target, BDNF. The gene for BDNF is a CREB target
whose protein product regulates synaptic function (Tao et al.,
1998). We found reduced BDNF levels in the hippocampus of
Tg2576 saline-treated mice and this reduction was amelio-
rated by sildenafil treatment. Nagahara’s group showed that
BDNF delivery ameliorated age-related cognitive impairment
in aged primates and mice even when the treatment is initi-
ated after disease onset (Nagahara et al., 2009). These authors
suggested that the mechanisms underlying BDNF actions are
independent of a direct modulation of amyloid processing
and include normalization of gene expression patterns, aug-
mentation of intracellular signalling and enhancement of
synaptic marker expression (Nagahara et al., 2009). In agree-
ment with our previous study (Puerta et al., 2010), sildenafil
significantly increased hippocampal BDNF levels in non-
transgenic mice, which may underlie the enhancement of
memory observed in the fear conditioning paradigm
(Figure 2F). Thus, we hypothesized that sildenafil could
replenish the pool of hippocampal BDNF. By contrast,
probably due to the time mice were killed (24 h after the last
sildenafil injection), no significant changes were detected in
hippocampal pCREB expression levels, as pCREB induction is
transient and probably had returned to basal levels when
samples were taken.
Arc is required for maintenance of long-term potentiation
and for memory consolidation (Lyford et al., 1995; Guzowski
and McGaugh, 1997; Steward and Worley, 2001). In relation
to the finding that sildenafil enhanced Arc expression only in
transgenic animals, we have to take in account that Ab
peptide modulates Arc expression (Lacor et al., 2004). Thus,
the presence of Ab may interfere with sildenafil in
co-modulating Arc expression levels. Moreover, activity-
dependent Arc protein is involved in neuronal homeostasis to
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maintain neuronal activity in an optimal dynamic range
(Shepherd and Bear, 2011). The scenario in wild-type mice
brain is different from that in transgenic mice brain; conse-
quently, the regulation of Arc expression by sildenafil may be
different in the two groups of animals.
In conclusion, in the Tg2576 model of AD, sildenafil
reversed the marked memory deficits of aged animals by
regulating the Akt/GSK3b and p25/CDK5 pathways. The
improvement of memory did not result from any decrease of
amyloid burden but, likely from an increase in the expression
of the synaptic-function regulating proteins BDNF and Arc.
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